WHO issues guidelines on GLP-1 therapies for obesity treatment: Understanding the impact, safety considerations, and who can benefit
This week, the World Health Organization entered a new arena with its first global guideline on GLP-1 therapies for obesity treatment. Released on December 1, 2025, the document conditionally recommends drugs like semaglutide, liraglutide, and tirzepatide for adults with a BMI of 30 or higher-but only as part of a lifelong plan that pairs them…
